CR20230204A - Composiciones y métodos para el tratamiento de la enfermedad ocular tiroidea - Google Patents

Composiciones y métodos para el tratamiento de la enfermedad ocular tiroidea

Info

Publication number
CR20230204A
CR20230204A CR20230204A CR20230204A CR20230204A CR 20230204 A CR20230204 A CR 20230204A CR 20230204 A CR20230204 A CR 20230204A CR 20230204 A CR20230204 A CR 20230204A CR 20230204 A CR20230204 A CR 20230204A
Authority
CR
Costa Rica
Prior art keywords
compositions
treatment
methods
eye disease
thyroid eye
Prior art date
Application number
CR20230204A
Other languages
English (en)
Inventor
Vahe Bedian
Peter Harwin
Tomas Kiselak
Angela She
Jonathan Violin
Yang Zhao
Original Assignee
Viridian Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viridian Therapeutics Inc filed Critical Viridian Therapeutics Inc
Publication of CR20230204A publication Critical patent/CR20230204A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En el presente documento se proporcionan anticuerpos y composiciones contra IGF-1R y los usos de los mismos.
CR20230204A 2020-10-14 2021-10-14 Composiciones y métodos para el tratamiento de la enfermedad ocular tiroidea CR20230204A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063091839P 2020-10-14 2020-10-14
US202163201978P 2021-05-21 2021-05-21
US202163260130P 2021-08-10 2021-08-10
US202163261742P 2021-09-28 2021-09-28
PCT/US2021/054907 WO2022081799A1 (en) 2020-10-14 2021-10-14 Compositions and methods for treatment of thyroid eye disease

Publications (1)

Publication Number Publication Date
CR20230204A true CR20230204A (es) 2023-10-11

Family

ID=81208791

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230204A CR20230204A (es) 2020-10-14 2021-10-14 Composiciones y métodos para el tratamiento de la enfermedad ocular tiroidea

Country Status (16)

Country Link
US (7) US20220267450A1 (es)
EP (1) EP4228616A1 (es)
JP (1) JP2023545520A (es)
KR (1) KR20230124550A (es)
AU (1) AU2021360889A1 (es)
CA (2) CA3195590A1 (es)
CL (1) CL2023001052A1 (es)
CO (1) CO2023005996A2 (es)
CR (1) CR20230204A (es)
DO (1) DOP2023000073A (es)
EC (1) ECSP23034914A (es)
IL (1) IL302068A (es)
MX (1) MX2023004280A (es)
PE (1) PE20231202A1 (es)
TW (2) TW202229350A (es)
WO (2) WO2022081804A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220267450A1 (en) * 2020-10-14 2022-08-25 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
WO2023019171A1 (en) * 2021-08-10 2023-02-16 Viridian Therapeutics, Inc. Compositions, doses, and methods for treatment of thyroid eye disease

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8153121B2 (en) 2000-10-06 2012-04-10 Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center Diagnosis and therapy of antibody-mediated inflammatory autoimmune disorders
EP1355919B1 (en) * 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US8034904B2 (en) * 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
TW200526684A (en) 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
EP2322215A3 (en) * 2004-07-16 2011-09-28 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
CN101287761A (zh) 2005-06-15 2008-10-15 先灵公司 抗-igf1r抗体制剂
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2008076257A2 (en) 2006-12-13 2008-06-26 Schering Corporation Treating cancer with anti-igflr antibody 19d12 = sch 717454
US20110014117A1 (en) 2007-06-28 2011-01-20 Schering Corporation Anti-igf1r
CA2758297A1 (en) * 2009-04-16 2010-10-21 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
CN102459347A (zh) 2009-05-01 2012-05-16 雅培制药有限公司 双重可变结构域免疫球蛋白及其用途
UY32808A (es) 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
EP2516624B1 (en) * 2009-12-23 2020-02-05 Merck Sharp & Dohme Corp. Cell line 3m
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
US20120263722A1 (en) 2010-11-04 2012-10-18 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
WO2012158657A1 (en) * 2011-05-18 2012-11-22 Merck Sharp & Dohme Corp. Therapeutic anti-igf1r combinations
WO2012158933A2 (en) 2011-05-18 2012-11-22 University Of Florida Research Foundation, Inc. Macrocycllc therapeutic agents and methods of treatment
ES2732213T3 (es) 2011-05-21 2019-11-21 Macrogenics Inc Moléculas que se unen a CD3 capaces de unirse a CD3 humano y no humano
MX2014008102A (es) 2011-12-30 2014-09-25 Abbvie Inc Inmunoglobulinas de dominio variable dual contra receptores.
SG11201404943PA (en) 2012-02-15 2014-10-30 Ecole Polytech Erythrocyte-binding therapeutics
US20150056191A1 (en) * 2012-03-30 2015-02-26 Merck Sharp & Dohme Corp. Igf1 biomarker for igf1r inhibitor therapy
WO2013191982A2 (en) 2012-06-21 2013-12-27 Sorrento Therapeutics Inc. Antigen binding proteins that bind igf1r
US20210138076A2 (en) 2014-01-27 2021-05-13 Molecular Templates, Inc. Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes
WO2017201449A1 (en) 2016-05-20 2017-11-23 Genentech, Inc. Protac antibody conjugates and methods of use
AR112600A1 (es) 2017-05-30 2019-11-20 Teijin Pharma Ltd Anticuerpo anti-receptor de igf-i
EP3700901A1 (en) 2017-10-24 2020-09-02 Genentech, Inc. (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof
WO2019084030A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
US11208489B2 (en) 2018-01-24 2021-12-28 Horizon Therapeutics Ireland Dac Methods for the treatment of thyroid eye disease
US20210284741A1 (en) 2018-01-24 2021-09-16 Hznp Limited Methods for the treatment of thyroid eye disease
WO2019173352A1 (en) * 2018-03-05 2019-09-12 Hznp Limited Methods for the treatment of thyroid eye disease
WO2019183523A1 (en) 2018-03-23 2019-09-26 Genentech, Inc. Hetero-bifunctional degrader compounds and their use as modulators of targeted ubiquination (vhl)
US20210261649A1 (en) 2018-06-29 2021-08-26 Krystal Biotech, Inc, Compositions and methods for antibody delivery
BR112021012094A2 (pt) * 2018-12-19 2021-08-31 Humabs Biomed Sa Anticorpos isolados, proteína de fusão, polinucleotídeos isolados, vetor, célula hospedeira, composição farmacêutica, kit, método de produção, usos, métodos de tratamento, prevenção e/ou atenuação, de diagnóstico in vitro e para detectar a presença ou ausência de um epítopo
EP4021500A4 (en) * 2019-08-28 2023-09-06 Horizon Therapeutics Ireland Dac METHOD FOR TREATING THYROID EYE DISEASE
US20220267450A1 (en) * 2020-10-14 2022-08-25 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease

Also Published As

Publication number Publication date
TW202228775A (zh) 2022-08-01
US20230279122A1 (en) 2023-09-07
US20220275096A1 (en) 2022-09-01
US20240043546A1 (en) 2024-02-08
PE20231202A1 (es) 2023-08-17
CA3195590A1 (en) 2022-04-21
US20220267451A1 (en) 2022-08-25
IL302068A (en) 2023-06-01
US20220235137A1 (en) 2022-07-28
MX2023004280A (es) 2023-06-23
CA3195512A1 (en) 2022-04-21
KR20230124550A (ko) 2023-08-25
ECSP23034914A (es) 2023-06-30
DOP2023000073A (es) 2023-09-29
JP2023545520A (ja) 2023-10-30
US20220267450A1 (en) 2022-08-25
US20230002495A1 (en) 2023-01-05
EP4228616A1 (en) 2023-08-23
WO2022081799A1 (en) 2022-04-21
US11548951B1 (en) 2023-01-10
AU2021360889A1 (en) 2023-06-15
CO2023005996A2 (es) 2023-05-29
CL2023001052A1 (es) 2023-11-17
TW202229350A (zh) 2022-08-01
WO2022081804A1 (en) 2022-04-21

Similar Documents

Publication Publication Date Title
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
CL2023001052A1 (es) Composiciones y métodos para el tratamiento de la enfermedad ocular tiroidea
PH12019500923A1 (en) Anti-pd-1 antibodies and compositions
EP4248996A3 (en) Anti-trem2 antibodies and methods of use thereof
MX2022002682A (es) Anticuerpos anti-cd73.
AU2017310412A8 (en) Method of improving connective tissue attachment using anti-sclerostin antibodies
AU2016348418A8 (en) Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same
CR20220329A (es) Anticuerpos anti–mertk y metodos de uso de los mismos
MX2021012692A (es) Anticuerpos anti-mertk y sus metodos de uso.
MX2018013525A (es) Construcciones de anticuerpo de adn para uso contra pseudomonas aeruginosa.
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
MX2020011176A (es) Metodos para tratar cancer con una combinacion de un anticuerpo anti-molecula de muerte programada 1 y un conjugado de anticuerpo anti-factor tisular-medicamento.
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.
MX2023007003A (es) Antigenos especificos de tejidos para la inmunoterapia del cancer.
MX2022001947A (es) Anticuerpos que se unen a las proteinas lrp5 y metodos de uso.
MX2021010665A (es) Metodos de tratamiento de amiloidosis al.
MX2023005841A (es) Anticuerpos anti-marco y usos de estos.
CL2021002866A1 (es) Tratamiento de la cefalea usando anticuerpos anti-cgrp.
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use
MX2021005751A (es) Anticuerpos contra mucina 16 y métodos de uso de los mismos.
MX2023014154A (es) Anticuerpos anti-ccr8.
MX2020013923A (es) Anticuerpos anti molécula de adhesión celular l1 (l1cam) y usos de estos.
WO2023133485A3 (en) Compositions and methods for treatment of thyroid eye disease
WO2023133486A3 (en) Compositions and methods for treatment of thyroid eye disease